Biocon: India's Largest Biopharma Focused on Affordable Innovation

Biocon is India's largest fully-integrated, innovation-led biopharmaceutical company that is driven by a passion to develop research-driven, cutting-edge therapies. The Company has taken the lead in India to harness the power of biotechnology through affordable innovation to find solutions that heal the world.

Over the years, Biocon has invested in cutting-edge science, key research partnerships and global manufacturing scale to develop products that address the various needs of patients worldwide. As an emerging global enterprise, Biocon is addressing the needs of patients through differentiated products in over 120 countries.

Biocon has invested majorly in cutting-edge research with the objective of reducing therapy costs for chronic conditions like diabetes, cancer and autoimmune diseases. The Company has successfully taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'.

The Company has played a crucial role in addressing the huge disease burden of diabetes by pioneering the development of INSUGEN^®, an indigenous recombinant human insulin (rh-insulin) based on proprietary fermentation technology. BASALOG^®, Biocon's long-acting Insulin Glargine, is also making a significant difference to diabetes management in India.

In the life-threatening segment of anti-cancer therapies, Biocon has delivered to patients India's first indigenously produced novel monoclonal antibody for head and neck cancer - BIOMAb EGFR^®. Taking its battle with cancer forward, Biocon has launched the world's most affordable biosimilar trastuzumab, CANMAb^™, for the treatment of HER2-positive breast cancer in India. CANMAb^™ is one of the most successful oncology product launches in India.

In the segment of autoimmune diseases, Biocon has introduced the world's first novel anti-CD6 monoclonal antibody, ALZUMAb^™, for the treatment of chronic plaque psoriasis. This molecule also holds promise for a range of other autoimmune diseases.

Biocon aims to double revenue to $1 billion by FY19 powered by its growth accelerators viz., Small Molecules, Biosimilars, Branded Formulations, Novel Molecules and Research Services, represented by its subsidiary Syngene.

The Small Molecules vertical consists of statins, immunosuppressants, speciality molecules like Fidaxomicin and other APIs.

The Biosimilars vertical consists of a high-value portfolio of generic insulin and analogs for diabetes and biosimilars for oncology and autoimmune indications. The portfolio aimed at diabetes consists of generic forms of rh-Insulin, Insulin Glargine, Insulin Lispro and Insulin Aspart. While Insulin Lispro and Insulin Aspart are in different stages of preclinical development, global clinical development for rh-Insulin and Glargine is progressing well.

Biocon, which is the fourth largest insulin producer in the world, is expanding capacity by setting up Asia's largest integrated insulins manufacturing and R&D facility in Malaysia to address the global need for biosimilar Insulins.

The portfolio for oncology and autoimmune indications consists of three biosimilar monoclonal antibodies (trastuzumab, bevacizumab and adalimumab) and two biosimilar recombinant proteins (pegylated-filgrastim and eternacept).

Branded Formulations is an India-centric business with global ambitions. With a portfolio of over 70 brands, the business is organized into five verticals around key therapy areas. The Company is aiming for market leadership in its chosen therapeutic areas through a carefully orchestrated strategy of product differentiation and personalized medical support.

On the novel molecules front, Biocon has entered exclusive and collaborative research and marketing agreements to develop and commercialize a basket of molecules globally. The pipeline includes a potentially game-changing oral insulin, being developed jointly with BMS.

Biocon has also built a remarkable Research Services business through Syngene that offers integrated discovery and development solutions for both small and large molecules to 16 of the world's top 20 biopharmaceutical companies, a large number of mid-sized biotech and pharma firms and several small and virtual enterprises.

Biocon's biggest strength is its 7,500+ strong talent pool, which includes the largest scientific community working out of a single site, at Biocon Park in Bangalore. In fact, Biocon has earned the global recognition of being among the World's Top 10 Best Biopharma Employers.

Biocon's efforts in providing better healthcare through affordable innovation do not stop at developing new medicines. Through Biocon Foundation the Company is engaged in promoting social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services, proper sanitation and educational opportunities.

Biocon's tryst with innovation has enabled it to cross new milestones in the area of drug affordability. In doing so, the Company has earned the trust of partners, doctors, patients, care givers and healthcare ecosystems around the world. A combination of tryst and trust has powered Biocon to reinforce its vision of emerging as a relevant global enterprise, delivering cutting-edge innovation that is affordable, available and accessible.